Nashville Maternal-Fetal Physician Group Acquired by Pediatrix

  
    
  
  
    
      Pediatrix Medical Group, Inc. (NYSE:PDX) has completed the acquisition 
      of Maternal-Fetal Group, PLLC, a physician group practice based in 
      Nashville, Tennessee, that provides patient care for women with 
      high-risk and complicated pregnancies. The group will practice as part 
      of Obstetrix Medical Group, a maternal-fetal medicine national medical 
      group that is part of Pediatrix.
    
    
      Maternal-Fetal Group consists of three physicians who provide patient 
      care at three offices in the Nashville metropolitan area. The practice 
      also has agreements to support referring obstetrical practices by 
      providing mobile ultrasound services at approximately 20 sites 
      throughout the metropolitan area. In addition to the physicians, 
      Maternal-Fetal Group also includes more than 40 clinical and 
      administrative staff members.
    
    
      Maternal-Fetal Group has participated in extensive research to identify 
      causes of premature labor, including an understanding of infections 
      associated with prenatal care, under the direction of Stephen J. 
      Fortunato, M.D.
    
    
      “Joining with a national group of 
      maternal-fetal physicians gives us the ability to take our practice to a 
      different level,” said Salvatore J. Lombardi, 
      M.D., who was one of Maternal-Fetal Group’s 
      founding physicians and will serve as Medical Director of Obstetrix in 
      Nashville. “The value added for our 
      subspecialty is the ability to support community-based obstetricians 
      with prenatal diagnosis of fetal and maternal problems. We expect that 
      our ability to collaborate with Obstetrix physicians across the country 
      to accelerate research and conduct clinical quality initiatives will 
      lead to improved outcomes for pregnant women in our community.”
    
    
      Pediatrix paid cash for Maternal-Fetal Group, and the practice is 
      expected to contribute to the Company’s 
      earnings immediately. Additional terms of the transaction were not 
      disclosed.
    
    
      Investor conference call
    
    
      Pediatrix Medical Group, Inc. will host an investor conference call to 
      discuss the Nashville acquisition, as well as other corporate 
      developments, at 10 a.m. (EDT) today. The conference call Webcast may be 
      accessed from the Company’s Website, www.pediatrix.com. 
      A telephone replay of the conference call will be available from noon 
      (EDT) today through midnight (EDT) October 15, 2008, by dialing 
      800-475-6701, access code 963245. The replay will also be available at www.pediatrix.com.
    
    
      About Pediatrix
    
    
      Pediatrix Medical Group, Inc. is the nation’s 
      leading provider of neonatal, maternal-fetal and pediatric physician 
      subspecialty services and recently expanded to include anesthesiology 
      services. Pediatrix physicians and advanced practitioners are reshaping 
      the delivery of care within the maternal-fetal, neonatal intensive care 
      and pediatric cardiology subspecialties, using evidence-based tools, 
      continuous quality initiatives and clinical research to enhance patient 
      outcomes and provide high-quality, cost-effective care. Founded in 1979, 
      its neonatal physicians provide services at more than 250 neonatal 
      intensive care units, and in many markets they collaborate with 
      affiliated maternal-fetal medicine, pediatric cardiology physician 
      subspecialists and pediatric intensivists to provide a clinical care 
      continuum. Combined, Pediatrix and its affiliated professional 
      corporations employ more than 1,200 physicians in 32 states and Puerto 
      Rico. Pediatrix is also the nation’s largest 
      provider of newborn hearing screens. Additional information is available 
      at www.pediatrix.com.
    
    
      Certain statements and information in this press release may be 
      deemed to be “forward-looking statements” 
      within the meaning of the Federal Private Securities Litigation Reform 
      Act of 1995. Forward-looking statements may include, but are not 
      limited to, statements relating to our objectives, plans and strategies, 
      and all statements (other than statements of historical facts) that 
      address activities, events or developments that we intend, expect, 
      project, believe or anticipate will or may occur in the future are 
      forward-looking statements. These statements are often characterized by 
      terminology such as “believe”, 
      “hope”, “may”, 
      “anticipate”, “should”, 
      “intend”, “plan”, 
      “will”, “expect”, 
      “estimate”, “project”, 
      “positioned”, “strategy” 
      and similar expressions, and are based on assumptions and assessments 
      made by Pediatrix’s management in light of 
      their experience and their perception of historical trends, current 
      conditions, expected future developments and other factors they believe 
      to be appropriate. Any forward-looking statements in this press release 
      are made as of the date hereof, and Pediatrix undertakes no duty to 
      update or revise any such statements, whether as a result of new 
      information, future events or otherwise. Forward-looking statements are 
      not guarantees of future performance and are subject to risks and 
      uncertainties. Important factors that could cause actual results, 
      developments, and business decisions to differ materially from 
      forward-looking statements are described in Pediatrix’s 
      most recent Annual Report on Form 10-K, including the section entitled “Risk 
      Factors”.